Sherry Rais, MSc, is a Management Consultant who helps startups, non-profit organizations, academic/research institutions, and small businesses raise funds, operate according to their Mission and Values, and implement processes that enhance their overall efficiency. Sherry believes in living and working in alignment with purpose and is currently focused on supporting organizations in the mental health/wellness space.

Sherry is a Co-Founder and the Co-CEO of Enthea, Executive Director the BPRG, and Grants Manager / Boston Coordinator at CIIS. She is a graduate of the CPTR Certificate program. Before entering the psychedelic field, Sherry consulted for over 10 years to the United Nations and World Bank as a social protection expert and project manager in over 30 countries. Sherry holds a Master’s Degree in Public Policy and Management from the London School of Economics and a Bachelor’s Degree in Psychology and International Development from McGill University.

Julia Mande is a facilitator and project manager for awareness-based systems change. She works with leaders in environmental, social, and corporate governance to align strategy with values. Julia has worked with the teams of L.A. Compost, A Growing Culture, and Collective Transitions.

She is trained in Regenerative Organizational Design and is actively in u.lab: Leading from the Emerging Future through MITx. Julia is a first-generation American, born in New York and raised in Zimbabwe, a daughter of emigrants from Morocco and the Southern African Jewish Diaspora.

Currently, Julia is stewarding the North Star Project, a nonprofit cultivating a culture of integrity in psychedelic business.

Ulf Bremberg is CEO and co-founder of Osmond Labs and a board member of Osmond Foundation. Ulf Bremberg has a 19-year background in industrial pharmaceutical development in pharma/biotech and has founded six companies. Earlier positions include Chief Scientific Officer at Beactica Tx, head of Lead Identification Facility at the national infrastructure SciLifeLab Drug Discovery & Development Platform, CEO of OncoTargeting AB, Chemistry Team Leader and Medicinal Chemist at Biovitrum and Pharmacia. Ulf Bremberg did his post-doc at the Scripps Research Institute and holds a Ph.D. in Organic Chemistry from KTH Royal Institute of Technology.

Rae Richman joined atai Life Sciences in 2021 as a Vice President and the head of its philanthropic arm, atai Impact.  Her role is to activate all of the company assets for social good, leveraging philanthropy, nonprofit partnerships, volunteerism, and atai-created programming.  

Previously Rae was the first Head of Global Citizenship at Airbnb, where she was responsible for activating all of the company’s assets for social good and launched their Diversity and Inclusion work.   Before joining Airbnb, she was the Vice President of the Bay Area office of Rockefeller Philanthropy Advisors (RPA), working with individuals, families and corporations on their giving, corporate social responsibility and impact investing programs. Rae is also passionate about facilitating community-based transformative experiences.   

Rae holds a Bachelor’s degree from the University of Virginia and Master’s in Business degrees from Columbia University and the University of California, Berkeley through the Berkeley/Columbia Executive MBA program.   Rae is a board member of Friends of the Earth US and was a founding Board Member of the Burning Man Project.

Next to his work with Osmond Labs, Frédéric has been a senior researcher and European R&D project coordinator at KTH, Sweden. In the context of psychedelic science and innovation, he is interested in bridging the gap between research and implementation in society

Born in Alsace, based in Berlin, Anne Philippi is a former author & reporter at Vanity Fair, GQ & VOGUE. She worked as a Silicon Valley correspondent for Frankfurter Allgemeine Zeitung and Frankfurter Allgemeine Quarterly. She lived in Los Angeles for six years reporting on Hollywood and the west coast tech world, creating a new storytelling around tech.

She discovered psychedelic-assisted therapy in 2019 and founded "The New Health Club Show” podcast and newsletter, created a space where people from the new psychedelic ecosystem and business could talk about the disruptive power of psychedelics. By 2021 she was part of the 100 most important people in psychedelics.

Now "The New Health Club" is working on introducing psychedelic tools into society and places such as the workspace, creating psychedelic coaching programs for C-Level and benefit programs for companies to offer to their employees.  

Ozan Polat is a Partner at Vine Ventures, a leading venture capital firm that invests in early-stage startups in the conscious health & wellness space.

Driven by his intrinsic curiosity, he previously co-founded Dezentrum, a think tank that researches & prototypes positive future scenarios for the digitized society of tomorrow and Trust Square, a technology hub in the heart of Zurich.

The same curiosity and hunger for innovative approaches to our society’s future drove him to Vine Ventures and its novel approach to health & wellness. Through its unique reciprocity pledge – where the fund donates 50% of its GP profits – and the inclusion of the entrepreneurs in the decision-making, Vine is charting a path for rethinking capitalistic structures more holistically.

Elliot Marseille is the President of the firm, Health Strategies International headquartered in Oakland, California that specializes in the economic evaluation of clinical and public health interventions. Trained in health policy analysis at the University of California, Berkeley, he has 35 years of senior public health management and research experience and has completed over 50 peer-reviewed publications.

In May of 2021, he became the founding Director of the Global Initiative for Psychedelic Science Economics (GIPSE), a combined UC Berkeley and UC San Francisco collaboration situated in the Center for Global Health Delivery Diplomacy and Economics. GIPSE is a network of health economists and health services researchers dedicated to achieving the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, GIPSE seeks to enhance clinical outcomes, efficiency of service delivery, and increase access to these promising therapies for everyone who can benefit.

An experienced Corporate Director and CEO: Doug has chaired the Board of a NASDAQ-listed company and, as CEO for the past 14 years, has built and turned around 4 pharmaceutical companies.

During Doug’s 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised around $4 billion of both public and private capital.

In 2008, Doug led the turnaround of Norwich Pharmaceuticals and became the Founding CEO of Alvogen. During his 5.5-year tenure as CEO, Doug transformed Norwich’s manufacturing, adding extensive R&D capabilities. At the same time, Alvogen grew from inception to $450 million in revenues across 35 countries, building an R&D facility in NJ, a Contract Research Organization in India, and creating a product development pipeline of over 50 products for the US market.

Doug holds a bachelor’s degree in Microbial and Molecular Biology from the University of East Anglia in the U.K. and was recognized as Entrepreneur of the Year by Ernst and Young, in 2012. Doug is an enthusiastic traveler, having traveled to over 70 countries, is an avid reader, and enjoys cooking and boating.

Robert Schoevers is a psychiatrist and epidemiologist with broad clinical experience and is currently head of the Department of Psychiatry at the University Medical Center Groningen, an academic mental health provider with substantial clinical and research facilities.

His research focuses on the epidemiology, underlying mechanisms and treatment of depressive disorder. My aim is to develop new interventions to conquer depression, which may range from prevention and early intervention to treatment of patients with Treatment-Resistant Depression (TRD). His team is involved in large epidemiological studies such as NESDA, TRAILS and LIFELINES and in their research combine these with clinical studies in patients and controls looking into symptomatology and underlying pathophysiology.

David Casimir counsels clients in all areas of intellectual property including patents, trademarks, copyrights, and trade secrets. A major focus of his practice is in the area of patent prosecution, post-issuance proceedings, litigation, litigation avoidance, due diligence, business counseling, and licensing with an emphasis in the biotechnology, pharmaceutical, chemical, medical device, and business methods fields.

Dr. Casimir has participated in the prosecution of over a thousand patent applications spanning topics such as molecular diagnostics, imaging systems, disease therapies, drugs, vaccines, drug delivery systems, research tools, enzymes, genes, artificial organs, transgenic animals, stem cells, nucleic acid synthesis, organic synthesis, multimedia information processing, material sciences, sensory substitution and enhancement, medical devices, nutraceuticals, ballistics systems, software, and Internet applications.

Dr. Casimir has worked with numerous small and large companies, universities, and institutes on all aspects of the intellectual property life cycle from procurement, post-issuance proceedings (re-examinations, re-issues, oppositions), strategic analysis, complex portfolio development, due diligence in funding rounds, IPOs, and mergers and acquisitions, licensing and negotiation, and litigation and dispute settlement.  Dr. Casimir has significant experience and expertise in managing large, complex patent portfolios and positioning such portfolios for withstanding scrutiny in litigation and due diligence analysis associated with funding or acquisition events.

Dr. Casimir has participated in numerous intellectual property lawsuits, representing both plaintiffs and defendants.  Dr. Casimir is also frequently engaged to provide freedom-to-operate opinions, including non-infringement and invalidity opinions.

Nicholas Brüss (MA, EdD) is an integrative psychotherapist and clinical researcher who specializes in helping people with psychedelics-assisted therapies. He is a therapist and supervisor on the MAPS-sponsored FDA Phase 3 clinical trial of MDMA-assisted therapy for PTSD in Los Angeles, California, USA. He is a leader in psychedelic-assisted Internal Family Systems (IFS) therapy and serves as an advisor at the intersection of psychedelic medicine and healthcare innovation.

Nicholas is the Co-founder and Lead Trainer of the Psychedelic Coalition for Health, an organization providing training in psychedelic-assisted therapy and integration for clinicians, and public education programs advocating for psychedelic medicine health and happiness.

Tadeusz Hawrot has spent 15 years working in the EU environment, leading the policy and advocacy work of several civil society organisations in the field of brain health. He was instrumental in setting up new advocacy alliances such as the National Brain Councils, Portuguese Societal Impact of Pain Platform and a global partnership OneNeurology. He is cooperating with WHO and other global health advocates. He is the founder of the Psychedelic Access and Research European Alliance (PAREA).

Tadeusz is the Founder and Policy Lead of PAREA which advocates for stepping up the European Union’s efforts to thoroughly assess the medicinal benefits of psychedelic compounds as safe, effective, and cost-efficient therapies as well as to better understand and mitigate associated risks.

Joost Breeksema is the executive director and co-founder of the OPEN Foundation, where he is focused on bringing together academics, clinicians, politicians and policy makers, in order to steer the integration of psychedelics in society and healthcare in a responsible and sustainable way. With years of experience in harm reduction and drug policy research, and a MA degree in philosophy, for his PhD he presently conducts qualitative research, interviewing patients about their treatment experiences with ketamine, psilocybin, and MDMA. His aim is to deepen our understanding of the potential therapeutic mechanisms involved and the role of setting, therapy, and other contextual factors in mitigating adverse effects. Underlying all his work is a deep-seated belief in the scientifically grounded, responsible and ethical integration of psychedelics that respects the multiplicity of other, non-medical approaches. He advocates for critical, collaborative, open, and transparent approaches in science and beyond.